

## $\alpha$ -Glucosidase Inhibitors from the Roots of *Sophora flavescens*

Tran Hong Quang,<sup>†,‡</sup> Nguyen Thi Thanh Ngan,<sup>†</sup> Chau Van Minh,<sup>‡</sup> Phan Van Kiem,<sup>‡</sup> Bui Huu Tai,<sup>†</sup>  
Nguyen Phuong Thao,<sup>†,‡</sup> Se-Uk Kwon,<sup>§</sup> Young-Mi Lee,<sup>§</sup> Hee-Kyoung Kang,<sup>#</sup> and Young Ho Kim<sup>†,\*</sup>

<sup>†</sup>College of Pharmacy, Chungnam National University, Daejeon 305-764, Korea. \*E-mail: yhk@cmu.ac.kr

<sup>‡</sup>Institute of Marine Biochemistry, Vietnam Academy of Science and Technology (VAST), 18 Hoang Quoc Viet, Cau Giay, Hanoi, Viet Nam

<sup>§</sup>Department of Oriental Pharmacy, College of Pharmacy and Wonkwang-Oriental Medicines Research Institute, Wonkwang University, Iksan, Jeonbuk 570-749, Korea

<sup>#</sup>School of Medicine, Institute of Medical Sciences, Jeju National University, Jeju 690-756, Korea

Received January 10, 2012, Accepted February 19, 2012

**Key Words :** *Sophora flavescens*, Leguminosae, Flavonoid,  $\alpha$ -Glucosidase, Anti-diabetic

Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose levels that result from defects in insulin secretion, or action, or both. Postprandial hyperglycemia has been an early indicator of abnormality in glucose metabolism leading to type 2-diabetes.<sup>1</sup> Therefore, reduction of postprandial hyperglycemia is critical in the early stage of diabetes therapy.<sup>2,3</sup> Since  $\alpha$ -glucosidase plays significant roles in the adjustment of insulin, inhibition of this enzyme has become one of the therapeutic targets to retard glucose absorption, finally resulting in suppression of postprandial hyperglycemia.<sup>4</sup> Therefore, suppressing carbohydrate digestion by the application of  $\alpha$ -glucosidase inhibitors (e.g. acarbose, miglitol, and voglibose) is considered an alternative treatment for diabetes.<sup>5</sup>

The dried roots of *S. flavescens* (Leguminosae) are commonly used as the traditional Chinese medicine and possess various physiological properties such as anti-bacterial, anti-inflammatory, antipyretic, anti-asthmatic, anti-ulcerative, and anti-neoplastic effects.<sup>6</sup> A series of isoprenylated or lavandulylated flavonoids have been isolated from this plant.<sup>7-12</sup> Some of these compounds exhibited significant antibacterial activity against Gram-positive bacteria,<sup>7</sup> antiviral activity against herpes simplex virus types I and II,<sup>8</sup> as well as cytotoxic activity against human myeloid leukemia HL-60 cells,<sup>10,12</sup> and potent inhibitory activity against cGMP phosphodiesterase 5.<sup>11</sup> The present study describes the isolation and structural elucidation of a new compound (**1**) and eight known compounds (**2-9**) from the methanol extract of the roots of *S. flavescens*. The inhibitory effect of the isolated compounds on the  $\alpha$ -glucosidase activity was evaluated.

The dried, chipped roots of *S. flavescens* were extracted with MeOH. The MeOH extract was suspended in water, and then partitioned with CH<sub>2</sub>Cl<sub>2</sub> and EtOAc successively to give CH<sub>2</sub>Cl<sub>2</sub> (A), EtOAc (B), and aqueous fractions (C), respectively. Fr. B was subjected to multiple column chromatography using silica gel and YMC C<sub>18</sub> to yield one new compound (**1**) and eight known compounds (**2-9**). The known compounds were identified to be isoxanthohumol (**2**),<sup>13</sup> norkurarinone (**3**),<sup>14</sup> kurarinone (**4**),<sup>15</sup> (2*S*)-2'-methoxykurarinone (**5**),<sup>10</sup> kushenol T (**6**),<sup>7</sup> norkurarinol (**7**),<sup>15</sup> kurari-

din (**8**),<sup>15</sup> and formononetin (**9**)<sup>16</sup> by comparison of the NMR and MS data with those reported in the literature.

Compound **1** was isolated as a yellow amorphous powder, and its molecular formula was established to be C<sub>21</sub>H<sub>22</sub>O<sub>6</sub> by HRESITOFMS at *m/z* 369.1320 [M-H]<sup>-</sup> (calcd for C<sub>21</sub>H<sub>21</sub>O<sub>6</sub>, 369.1338). The IR spectrum of **1** revealed hydroxyl and carbonyl groups based on absorption bands at 3279 and 1605 cm<sup>-1</sup>, respectively. The <sup>1</sup>H NMR spectrum of **1** showed an aromatic proton singlet at  $\delta_H$  6.10 (H-6), and a typical A<sub>2</sub>B<sub>2</sub> system at  $\delta_H$  6.73 (2H, d, *J* = 8.4 Hz, H-3', 5') and 7.28 (2H, d, *J* = 8.4 Hz, H-2', 6'). The <sup>1</sup>H NMR of **1** further showed the signals of a 3,3-dimethylallyl group at  $\delta_H$  1.58 (3H, s, H<sub>3</sub>-5''), 1.61 (3H, s, H<sub>3</sub>-4''), 3.22 (2H, m, H-1''), and 5.12 (1H, t, *J* = 7.2 Hz, H-2''). The position of 3,3-dimethyl-





Figure 1. Structures of compounds 1-9.



**Figure 2.** Key HMBC correlations of compound **1**.

allyl group was assigned to C-8 by the HMBC correlations from H<sub>2</sub>-1" to C-7 ( $\delta_C$  164.4), C-8 ( $\delta_C$  109.8), and C-9 ( $\delta_C$  162.7). The signals of a methoxyl group at 3.75 (3H, s) and two oxymethine groups at 5.37 (1H, d,  $J = 3.6$  Hz, H-2) and 4.24 (1H, d,  $J = 3.6$  Hz, H-3) were also observed in the <sup>1</sup>H NMR spectrum of **1**. The methoxyl group was determined to locate at C-5 based on the HMBC correlation of signal at  $\delta_H$  3.75 with  $\delta_C$  161.9 (C-5). The small coupling constant ( $J = 3.6$  Hz) of H-2 and H-3 revealed that these protons are located on the same side. The absolute configurations of H-2 and H-3 were determined by CD spectrum. The CD spectrum of **1** showed positive and negative Cotton effects at 341.4 and 274.2 nm, respectively. These signs and positions are in good agreement with those of the reported compound, (2*R*,3*S*)-*cis*-dihydrokaempferol,<sup>17,18</sup> indicating the absolute configurations of C-2 and C-3 to be *R* and *S*, respectively. Based on the above evidence, together with comparison of the NMR data of **1** with those of similar compound,<sup>19</sup> the structure of **1** was established as (2*R*)-3 $\alpha$ ,7,4'-trihydroxy-5-methoxy-8-( $\gamma,\gamma$ -dimethylallyl)-flavanone.

$\alpha$ -Glucosidases are enzymes that digest dietary carbohydrates in the small intestine and hence the inhibitors of this enzyme can delay the absorption of carbohydrates in food to suppress postprandial hyperglycemia. The effects of the isolated compounds on the inhibition of  $\alpha$ -glucosidases activity were evaluated. The result showed that compound **8** was most effective with IC<sub>50</sub> value of 3.6  $\mu$ M, whereas compounds **3-7** displayed similar inhibitory effects with IC<sub>50</sub> values in a range of 14.0-18.0  $\mu$ M. Based on the comparison of the structures and activities of the tested compounds, we found that all the 8-lavandulyl flavanone (**3-5**), 8-(5-hydroxy-2-isopropenyl-5-methylhexyl) flavanone (**6** and **7**), and 8-lavandulyl chalcone (**8**) significantly inhibited  $\alpha$ -glucosidase activity, while two 8-dimethylallyl flavanones (**1** and **2**) and an isoflavone (**9**) were inactive. Thus, the lavandulyl or 5-hydroxy-2-isopropenyl-5-methylhexyl group at C-8 is essential for the  $\alpha$ -glucosidase inhibitory effect of the flavanone compounds.

In conclusion, these results provide a scientific support for the use of the roots of *S. flavescens* and warrant further studies to develop new agents for the prevention and treatment of the diabetes.

## Experimental

**General Procedures.** Optical rotation was determined using a Jasco DIP-370 digital polarimeter. The FT-IR spectra were measured using a Jasco Report-100 infrared spectro-

meter. Electrospray ionization (ESI) mass spectra were obtained using an Agilent 1200 LC-MSD Trap spectrometer. HR-ESI-TOF mass spectra were obtained using a JEOL JMS-T100LC spectrometer. The NMR spectra were recorded on a Jeol ECA 600 spectrometer using TMS as an internal standard. CD spectra were recorded with a Jasco J-720 spectropolarimeter. TLC was performed on Kieselgel 60 F254 (1.05715; Merck, Darmstadt, Germany) or RP-18 F254s (Merck) plates. Spots were visualized by spraying with 10% aqueous H<sub>2</sub>SO<sub>4</sub> solution, followed by heating. Column chromatography (CC) was performed on silica gel (Kieselgel 60, 70-230 mesh and 230-400 mesh, Merck) and YMC RP-18 resins.

**Plant Materials.** The roots of *S. flavescens* was purchased from herbal market at Kumsan, Chungnam, Korea, in August 2010. The plant material was identified by one of us (Y. H. Kim). A voucher specimen (CNU10106) was deposited at herbarium, College of Pharmacy, Chungnam National University.

**Extraction and Isolation.** The dried stem bark of *S. flavescens* (3 kg) was extracted with hot MeOH. After concentration, the MeOH extract (250 g) was suspended in water and then partitioned successively with CH<sub>2</sub>Cl<sub>2</sub> and EtOAc to give CH<sub>2</sub>Cl<sub>2</sub> (A), EtOAc (B) and water (C) fractions, respectively. Fraction B was subjected to silica gel column chromatography, eluted with acetone in CH<sub>2</sub>Cl<sub>2</sub> (0-100%, stepwise) to yield five fractions (B1-5). Fraction B2 was then separated by column chromatography over YMC reverse-phase, using MeOH-H<sub>2</sub>O (2:1) to afford **8** (30 mg) and **9** (15 mg). Fraction B3 was separated by column chromatography over silica gel, using CH<sub>2</sub>Cl<sub>2</sub>-EtOAc (4:1) as eluent to give three subfractions (B3A-C). Subfraction B3A was chromatographed over silica gel column, eluting with CH<sub>2</sub>Cl<sub>2</sub>-acetone (5:1) to provide **3** (50 mg). Subfraction B3B was then chromatographed over YMC reverse-phase, using MeOH-H<sub>2</sub>O (3:1), and further purified by column chromatography over silica gel, eluting with CH<sub>2</sub>Cl<sub>2</sub>-MeOH (15:1) to obtain **1** (12 mg) and **6** (7 mg). Subfraction B3C was separated by YMC reverse-phase chromatography, using MeOH-H<sub>2</sub>O (2:1) as eluent, and further purified by column chromatography over silica gel, eluting with CH<sub>2</sub>Cl<sub>2</sub>-MeOH (12:1) to obtain **2** (10 mg) and **7** (45 mg). Fraction B4 was separated by column chromatography over silica gel, eluted with CH<sub>2</sub>Cl<sub>2</sub>-Acetone (4:1) to provide three subfractions (B4A-C). Subfraction B4B was then purified by column chromatography over YMC reverse-phase, using MeOH-H<sub>2</sub>O (2:1) to afford **4** (45 mg) and **5** (10 mg).

**(2*R*)-3 $\alpha$ ,7,4'-Trihydroxy-5-methoxy-8-( $\gamma,\gamma$ -dimethylallyl)-flavanone (**1**):** pale yellow, amorphous powder;  $[\alpha]_D^{25} -71.5$  ( $c$  0.25, MeOH); FT-IR (CH<sub>3</sub>CN)  $\nu_{\max}$  3279, 2968, 1605, 1599, 1516, 1256, 1087, 816 cm<sup>-1</sup>. HRESITOFMS  $m/z$  369.1320 [M-H]<sup>-</sup> (calcd for C<sub>21</sub>H<sub>21</sub>O<sub>6</sub>, 369.1338). CD (MeOH) nm ( $\Delta\epsilon$ ): 341.4 (+39.93), 274.2 (-26.60), 242.2 nm (-25.45). <sup>1</sup>H NMR (methanol-*d*<sub>4</sub>, 600 MHz) and <sup>13</sup>C NMR data (methanol-*d*<sub>4</sub>, 150 MHz), see Table 1.

**Isoxanthohumol (**2**):** pale yellow, amorphous powder,  $[\alpha]_D^{25} -25$  ( $c = 0.5$ , MeOH).

**Table 1.** NMR data for compound 1

Position	$\delta_C^{a,b}$	DEPT	$\delta_H^{a,c}$	HMBC
2	82.0	CH	5.37 d (3.6)	C-3, 4, 1', 2', 6'
3	74.1	CH	4.24 d (3.6)	C-2, 4, 1'
4	192.2	C		
5	161.9	C		
6	93.4	CH	6.10 br s	C-5, 7, 8, 10
7	164.4	C		
8	109.8	C		
9	162.7	C		
10	104.0	C		
1'	128.3	C		
2'	129.7	CH	7.28 d (8.4)	C-2, 4', 6'
3'	115.8	CH	6.73 d (8.4)	C-2', 4', 5'
4'	158.2	C		
5'	115.8	CH	6.73 d (8.4)	C-3', 4', 6'
6'	129.7	CH	7.28 d (8.4)	C-2, 2', 4'
1''	22.6	CH <sub>2</sub>	3.22 m	C-7, 8, 9, 2'', 3''
2''	123.9	CH	5.12 t (7.2)	C-8, 1'', 4'', 5''
3''	131.7	C		
4''	25.9	CH <sub>3</sub>	1.58 s	C-2'', 3'', 5''
5''	17.9	CH <sub>3</sub>	1.61 s	C-2'', 3'', 4''
5-OCH <sub>3</sub>	56.0	CH <sub>3</sub>	3.75 s	C-5

<sup>a</sup>Recorded in CD<sub>3</sub>OD. <sup>b</sup>150 MHz. <sup>c</sup>600 MHz. *J* values (Hz) are in parentheses.

**Norkurarione (3):** yellow, amorphous powder,  $[\alpha]_D^{25} +10.3$  (*c* = 0.7, MeOH).

**Kurarione (4):** yellow, amorphous powder,  $[\alpha]_D^{25} +13.5$  (*c* = 0.2, MeOH).

**(2S)-2'-Methoxykurarinone (5):** pale yellow, amorphous powder,  $[\alpha]_D^{25} -35.2$  (*c* = 0.1, MeOH).

**Kushenol T (6):** yellow, amorphous powder,  $[\alpha]_D^{25} -118.5$  (*c* = 0.2, MeOH).

**Norkurarinol (7):** yellow, amorphous powder,  $[\alpha]_D^{25} -25.5$  (*c* = 0.1, MeOH).

**Kuraridin (8):** yellow, amorphous powder,  $[\alpha]_D^{25} -25.5$  (*c* = 0.1, MeOH).

**Formononetin (9):** pale yellow, amorphous powder.

**Table 2.**  $\alpha$ -Glucosidase inhibitory effects of compounds 1-9

Compound	IC <sub>50</sub> ( $\mu$ M)
1	107.8 $\pm$ 5.7
2	86.9 $\pm$ 6.1
3	17.7 $\pm$ 2.6
4	14.5 $\pm$ 1.3
5	14.0 $\pm$ 1.2
6	16.7 $\pm$ 2.1
7	18.0 $\pm$ 1.5
8	3.6 $\pm$ 0.8
9	119.6 $\pm$ 9.4
Acarbose	2.9 $\pm$ 0.2

The values are mean  $\pm$  SD (*n* = 3).

**Inhibition Assay for  $\alpha$ -Glucosidase Activity.** A mixture of samples (50  $\mu$ L), 0.1 M phosphate buffer (pH 7.0, 50  $\mu$ L) containing  $\alpha$ -glucosidase solution (0.3 U/mL), and distilled water (50  $\mu$ L) was incubated in 96 well plates at 37 °C for 15 min. Then a solution of 3 mM *p*-NPG in 0.1 M phosphate buffer (pH 7.0, 100  $\mu$ L) was added to each well. The reaction mixtures were incubated at 37 °C for 10 min and stopped by adding 0.1 M Na<sub>2</sub>CO<sub>3</sub>. The absorbance was recorded at 405 nm by FLUOstar Optima (BMG Labtech, Offenburg, Germany). The results were expressed as a percent of  $\alpha$ -glucosidase inhibition and calculated according to the following equation:

$$\% \text{ inhibition} = [(\text{Abs}^{\text{control}} - \text{Abs}^{\text{extract}}) / \text{Abs}^{\text{control}}] \times 100$$

Acarbose was used as a positive control.

**Acknowledgments.** This work was supported by a grant from the Priority Research Center Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2009-0093815), Republic of Korea.

## References

- Labonte, E. D.; Kirby, R. J.; Schildmeyer, N. M.; Cannon, A. M.; Huggins, K. W.; Hui, D. Y. *Diabetes* **2006**, *55*, 935.
- Baron, A. D. *Diabetes Res. Clin. Pract.* **1998**, *40*, S51.
- Lebovitz, H. E. *Am. J. Cardiol.* **2001**, *88*, 20H.
- Yu, Z.-P.; Yin, Y.-G.; Zhao, W.-Z.; Yu, Y.-D.; Liu, B.-Q.; Liu, J.-B.; Chen, F. *Food Chem.* **2011**, *129*, 1376.
- Bhandari, M. R.; Jong-Anurakkun, N.; Hong, G.; Kawabata, J. *Food Chem.* **2008**, *106*, 247.
- Chang, H. M.; But, P. P. H. World Scientific Publishers: Philadelphia, 1986.
- Kuroyanagi, M.; Arakawa, T.; Hirayama, Y.; Hayashi, T. *J. Nat. Prod.* **1999**, *62*, 1595.
- Woo, E. R.; Kwak, J. H.; Kim, H. J.; Park, H. *J. Nat. Prod.* **1998**, *61*, 1552.
- Kang, S. S.; Kim, J. S.; Son, K. H.; Chang, H. W.; Kim, H. P. *Fitoterapia* **2000**, *71*, 511.
- Kang, T. H.; Jeong, S. J.; Ko, W. G.; Kim, N. Y.; Lee, B. H.; Inagaki, M.; Miyamoto, T.; Higuchi, R.; Kim, Y. C. *J. Nat. Prod.* **2000**, *63*, 680.
- Shin, H. J.; Kim, H. J.; Kwak, J. H.; Chun, H. O.; Kim, J. H.; Park, H.; Kim, D. H.; Lee, Y. S. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 2313.
- Ko, W. G.; Kang, T. H.; Kim, N. Y.; Lee, S. J.; Kim, Y. C.; Ko, G. I.; Ryu, S. Y.; Lee, B. H. *Toxicol. In Vitro* **2000**, *14*, 429.
- Jeong, T. S.; Ryu, Y. B.; Kim, H. Y.; Curtis-Long, M. J.; An, S. J.; Lee, J. H.; Lee, W. S.; Park, K. H. *Biol. Pharm. Bull.* **2008**, *31*, 2097.
- Hillerns, P. I.; Wink, M. *Planta Med.* **2005**, *71*, 1065.
- Ryu, S. Y.; Lee, H. S.; Kim, Y. K.; Kim, S. H. *Arch. Pharm. Res.* **1997**, *20*, 491.
- Hwang, J. S.; Lee, S. A.; Hong, S. S.; Lee, K. S.; Lee, M. K.; Hwang, B. Y.; Ro, J. S. *Arch. Pharm. Res.* **2005**, *28*, 190.
- Prescott, A. G.; Stamford, N. P.; Wheeler, G.; Firmin, J. L. *Phytochemistry* **2002**, *60*, 589.
- Slade, D.; Ferreira, D.; Marais, J. P. *Phytochemistry* **2005**, *66*, 2177.
- Jung, H. J.; Kang, S. S.; Hyun, S. K.; Choi, J. S. *Arch. Pharm. Res.* **2005**, *28*, 534.